Khiron Life Sciences (KHRN.V) wisely spent 2018 laying the groundwork for its continued expansion throughout the Americas. As Abraham Lincoln once said, “Give me six hours to chop down a tree and I will spend the first four sharpening the ax.”
Equity.Guru’s Ethan Reyes spoke with Khiron president, Chris Naprawa, to discuss the company’s progress in 2018, the tantalizing Brazilian market and what the sector can expect from Khiron in 2019.
Full disclosure: Khiron Life Sciences is an Equity.Guru marketing client.Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Ethan Reyes (see all)
- ‘Crazy’ Joe Biden may be standing in the way of the eventual U.S. cannabis explosion - November 21, 2019
- SOL Global (SOL.C) files early warning report for acquisition of Torque (GAME.V) shares - November 13, 2019
- Cresco Labs (CL.C) reprices Origin House (OH.C) acquisition terms to match declining market - November 13, 2019